Since 2009, the ACCME has supported the role of accredited CME as a strategic asset to risk evaluation and mitigation strategies (REMS) for FDA-approved products, provided the proper controls are in place to ensure independence. Throughout the process of developing the Extended-Release and Long-Acting (ER/LA) Opioid Analgesics REMS, the ACCME has continued to support the CE community’s role in contributing to this important public health initiative. The ACCME has provided interpretations of its requirements and worked with the FDA and other continuing education accreditors to align expectations and to develop aligned data collection systems for use by accredited providers. The ACCME will continue to collaborate with continuing education accreditors and credit systems to facilitate and support accredited education about the ER/LA Opioid Analgesics REMS. The ACCME will continue to provide support and guidance, including interpretations of the ACCME Standards for Commercial Support, for accredited providers that choose to develop CME that supports the ER/LA Opioid Analgesics REMS.
